NASDAQ:AVTX Avalo Therapeutics (AVTX) Stock Price, News & Analysis $4.88 -0.07 (-1.41%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Avalo Therapeutics Stock (NASDAQ:AVTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Avalo Therapeutics alerts:Sign Up Key Stats Today's Range$4.77▼$5.0850-Day Range$4.41▼$8.7352-Week Range$4.15▼$17.49Volume38,255 shsAverage Volume53,916 shsMarket Capitalization$52.08 millionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingModerate Buy Company OverviewAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Read More… Avalo Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreAVTX MarketRank™: Avalo Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 328th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingAvalo Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAvalo Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Avalo Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Avalo Therapeutics are expected to grow in the coming year, from ($19.07) to ($4.70) per share.Price to Book Value per Share RatioAvalo Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Avalo Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.36% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 20.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAvalo Therapeutics does not currently pay a dividend.Dividend GrowthAvalo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.36% of the float of Avalo Therapeutics has been sold short.Short Interest Ratio / Days to CoverAvalo Therapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Avalo Therapeutics has recently increased by 20.27%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.21 News SentimentAvalo Therapeutics has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Avalo Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for AVTX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Avalo Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Avalo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.25% of the stock of Avalo Therapeutics is held by insiders.Percentage Held by Institutions87.06% of the stock of Avalo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Avalo Therapeutics' insider trading history. Receive AVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avalo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AVTX Stock News HeadlinesAnalysts Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Price Target at $33.00April 24 at 1:45 AM | americanbankingnews.comSeven new option listings and one option delisting on April 16thApril 17, 2025 | markets.businessinsider.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 24, 2025 | Porter & Company (Ad)Avalo Therapeutics Reports 2024 Financial ResultsApril 16, 2025 | tipranks.comAvalo Therapeutics initiated with a Buy at JefferiesMarch 26, 2025 | markets.businessinsider.comAvalo Therapeutics Appoints Michael Heffernan as Chairman of the BoardMarch 26, 2025 | globenewswire.comStifel initiates Avalo Therapeutics stock with a Buy ratingMarch 26, 2025 | investing.comStifel Initiates Coverage of Avalo Therapeutics (AVTX) with Buy RecommendationMarch 25, 2025 | msn.comSee More Headlines AVTX Stock Analysis - Frequently Asked Questions How have AVTX shares performed this year? Avalo Therapeutics' stock was trading at $7.43 at the start of the year. Since then, AVTX stock has decreased by 34.3% and is now trading at $4.88. View the best growth stocks for 2025 here. How were Avalo Therapeutics' earnings last quarter? Avalo Therapeutics, Inc. (NASDAQ:AVTX) posted its quarterly earnings data on Monday, August, 12th. The company reported ($14.07) EPS for the quarter, missing the consensus estimate of ($6.70) by $7.37. When did Avalo Therapeutics' stock split? Avalo Therapeutics's stock reverse split on the morning of Friday, December 29th 2023. The 1-240 reverse split was announced on Friday, December 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. How do I buy shares of Avalo Therapeutics? Shares of AVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Avalo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Avalo Therapeutics investors own include Sangamo Therapeutics (SGMO), FuelCell Energy (FCEL), Canoo (GOEV), Aurora Cannabis (ACB), Agenus (AGEN), Meta Platforms (META) and Geron (GERN). Company Calendar Last Earnings8/12/2024Today4/24/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AVTX CIK1534120 Webwww.avalotx.com Phone(410) 522-8707FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$48.00 Low Stock Price Target$18.00 Potential Upside/Downside+576.2%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,540,000.00 Net MarginsN/A Pretax Margin-972.77% Return on Equity-442.16% Return on Assets122.99% Debt Debt-to-Equity RatioN/A Current Ratio1.42 Quick Ratio1.42 Sales & Book Value Annual Sales$441,000.00 Price / Sales118.09 Cash FlowN/A Price / Cash FlowN/A Book Value$9.11 per share Price / Book0.54Miscellaneous Outstanding Shares10,672,000Free Float10,368,000Market Cap$52.08 million OptionableNot Optionable Beta0.72 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:AVTX) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersTop Picks for Trump’s Pro-Crypto AmericaJust Announced: What Trump’s Move Means for Crypto—Join Now 27 top names reveal urgent insights as Bitcoin ...Crypto 101 Media | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.